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Oral Delivery of Bioencapsulated Proteins Across Blood–Brain and Blood–Retinal
Barriers
Abstract
Delivering neurotherapeutics to target brain-associated diseases is a major challenge. Therefore, we
investigated oral delivery of green fluorescence protein (GFP) or myelin basic protein (MBP) fused with
the transmucosal carrier cholera toxin B subunit (CTB), expressed in chloroplasts (bioencapsulated within
plant cells) to the brain and retinae of triple transgenic Alzheimer's disease (3×TgAD) mice, across the
blood–brain barriers (BBB) and blood–retinal barriers (BRB). Human neuroblastoma cells internalized
GFP when incubated with CTB-GFP but not with GFP alone. Oral delivery of CTB-MBP in healthy and
3×TgAD mice shows increased MBP levels in different regions of the brain, crossing intact BBB. Thioflavin
S–stained amyloid plaque intensity was reduced up to 60% by CTB-MBP incubation with human AD and
3×TgAD mice brain sections ex vivo. Amyloid loads were reduced in vivo by 70% in hippocampus and
cortex brain regions of 3×TgAD mice fed with bioencapsulated CTB-MBP, along with reduction in the ratio
of insoluble amyloid β 42 (Aβ42) to soluble fractions. CTB-MBP oral delivery reduced Aβ42 accumulation
in retinae and prevented loss of retinal ganglion cells in 3×TgAD mice. Lyophilization of leaves increased
CTB-MBP concentration by 17-fold and stabilized it during long-term storage in capsules, facilitating lowcost oral delivery of therapeutic proteins across the BBB and BRB.
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Oral Delivery of Bioencapsulated Proteins Across
Blood–Brain and Blood–Retinal Barriers
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Ping Zhu2, Sic L Chan1, Qiuhong Li2 and Henry Daniell1
1
School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 2Department of Ophthalmology, College of Medicine,
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Delivering neurotherapeutics to target brain-associated
diseases is a major challenge. Therefore, we investigated
oral delivery of green fluorescence protein (GFP) or
myelin basic protein (MBP) fused with the transmucosal carrier cholera toxin B subunit (CTB), expressed in
chloroplasts (bioencapsulated within plant cells) to the
brain and retinae of triple transgenic Alzheimer’s disease (3×TgAD) mice, across the blood–brain barriers
(BBB) and blood–retinal barriers (BRB). Human neuroblastoma cells internalized GFP when incubated with
CTB-GFP but not with GFP alone. Oral delivery of CTBMBP in healthy and 3×TgAD mice shows increased MBP
levels in different regions of the brain, crossing intact
BBB. Thioflavin S–stained amyloid plaque intensity was
reduced up to 60% by CTB-MBP incubation with human
AD and 3×TgAD mice brain sections ex vivo. Amyloid
loads were reduced in vivo by 70% in hippocampus and
cortex brain regions of 3×TgAD mice fed with bioencapsulated CTB-MBP, along with reduction in the ratio of
insoluble amyloid β 42 (Aβ42) to soluble fractions. CTBMBP oral delivery reduced Aβ42 accumulation in retinae
and prevented loss of retinal ganglion cells in 3×TgAD
mice. Lyophilization of leaves increased CTB-MBP concentration by 17-fold and stabilized it during long-term
storage in capsules, facilitating low-cost oral delivery of
therapeutic proteins across the BBB and BRB.
Received 2 September 2013; accepted 19 November 2013; advance online
publication 7 January 2014. doi:10.1038/mt.2013.273

INTRODUCTION

Drug delivery of biologics from bloodstream to the brain across
the blood–brain barrier (BBB) has long been a major challenge
to treat neuronal degenerative disorders.1–3 Invasive approach
to bypass the BBB includes intracerebro-ventricular infusion,
convection-enhanced delivery, or microchip systems to release
such therapeutics. However, these strategies are neither efficient
to deliver optimal concentrations of drug to the brain parenchyma, nor patient friendly, enhancing tumor dissemination.4
Modification of chemical properties of drugs can facilitate penetration across BBB but often results in losing the desired central nervous system (CNS) activity.2,4 Although the transcytosis

mechanism4 across polarized endothelial cells at BBB is not clear,
selection of high-affinity ganglioside M1 (monosialotetrahexosyl)
receptor (GM1) binding ligands, like the cholera toxin B subunit
(CTB), should address the process of transcytosis across BBB.
However, no attention has been paid for developing oral drug
delivery systems to address neurological diseases.
Likewise, ocular drug delivery, particularly to the posterior segment of the eye, is also a major challenge due to several anatomical
and physiological constrains of the eye.5,6 Topically administered
drug cannot reach the retina and vitreous cavity because of the
ocular surface barriers, which include cornea epithelium, stroma,
and endothelial layers, continuous tear drainage, frontward flow of
aqueous humor, and surrounding blood circulations, all limiting
the penetration of topically administered drug. Although intravenous administration is extensively used for delivering drugs to
the posterior part of the eye, ocular pharmacologists face major
obstacles7 such as retinal detachment, endophthalmitis, and high
intraocular pressure through this accessible route.
Alzheimer’s disease (AD) is the most common neurodegenerative disease and the sixth leading cause of death in the United States,
affecting an estimated 5.4 million Americans and 36 million people globally,8 with treatment cost exceeding US$600 billion, posing
a major health-care challenge. By the year 2050, it is estimated that
the incidence of AD will reach >100 million patients worldwide.9
One of the major pathological hallmarks of AD is the deposition of
amyloid β 42 (Aβ42) as extracellular neuronal plaques.10 The Aβ42
peptide is produced by the sequential cleavage of amyloid precursor protein within lipid rafts by endoproteolytic enzymes β and γ
secretase, respectively.11 Following the cleavage of amyloid precursor protein, Aβ fragments of different lengths Aβ42, Aβ38, and
even Aβ46 are produced, with the predominant form being Aβ40.12
Although Aβ42 is a minor species, it has a greater propensity to
aggregate and form plaques. This leads to a detrimental loss of
synaptic structural integrity/communication between axon and
dendrites, contributing to cognitive dysfunction leading to neuronal degeneration.13 Current US Food and Drug Administration–
approved pharmacotherapies provide some symptomatic benefits,
but they do not prevent disease progression.14
Furthermore, visual abnormalities are also prevalent among
AD patients. Visual disturbances in AD patients include impaired
motion and depth perception, spatial contrast sensitivity and color
recognition,15 associated with degeneration and loss of retinal
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ganglion cells (RGCs) and reduction of retinal nerve fibers.16
Aβ deposition in the retina appeared to be associated with RGC
apoptosis and retinal structural and functional impairment.16 In
addition, Aβ deposits have been reported in glaucomatous optic
nerve heads, drusen of age-related macular degeneration, and lens
with cataracts.17–20 Intravitreal injection of Aβ causes RGC damage, illustrating Aβ toxicity to retinal tissue.21 Therefore, for diagnosis of AD, retinal scans have been used to identify Aβ plaque
deposits.
Recently, the US Food and Drug Administration approved a
carrot cell–based system for production of the first human therapeutic protein.22 Oral delivery of chloroplast-derived therapeutics
bioencapsulated in plant cells eliminates the need for expensive
fermentation, purification, cold storage and transportation, and
sterile delivery.23 Bioencapsulation of therapeutic proteins by
plant cell wall ensures their protection from proteolytic degradation in the stomach and facilitates their delivery to the circulatory
system by the action of commensal microbes and receptors present in the gut.23 The delivery of fusion proteins across intestinal
epithelium is facilitated by transmucosal carrier, CTB by binding
to the ganglioside receptor.24 Here we report for the first time, the
oral delivery of bioencapsulated reporter and therapeutic proteins
across BBB and blood–retinal barriers (BRB).
Myelin basic protein (MBP), a major structural protein of
CNS comprising ~30% of the total myelin protein, is essential for
the formation of CNS myelin,25 contributing to the stability and
maintenance of the sheath. In the early stages of AD, focal demyelination associated with Aβ plaques in white matter is observed in
both human tissue and relevant murine models but not in plaquefree areas.26 Moreover, MBP has also been shown in vitro to possess intrinsic protease activity capable of degrading Aβ amyloid
and the ability to bind Aβ amyloid and inhibit Aβ fibril formation.27,28 Bioencapsulated MBP fused with CTB is hypothesized to
cross the BBB in vivo and degrade Aβ aggregates. Therefore, in
this study, we investigate oral delivery of bioencapsulated CTBMBP in mouse or human brains with advanced AD for delivery
across BBB and BRB.

RESULTS
Characterization of CTB-MBP protein expressed in
chloroplasts

The CTB-MBP construct is based on the plasmid (Lee/Daniell)
(pLD) vector with trnI-trnA flanking sequences to facilitate
homologous recombination,29 and the gene of interest is regulated by the psbA promoter and 5′ untranslated region to achieve
high-level expression. In the fusion construct, glycine–proline–
glycine–proline hinge prevented steric hindrance between two
proteins, psbA 3′ untranslated region provided transcript stability, the aadA gene and ribosome binding site conferred spectinomycin resistance for selection (Figure 1a). Transplastomic plants
were produced through particle bombardment as described earlier.30 Transplastomic lines were confirmed by Southern blots
conferring site-specific integration of transgene into the spacer
region between trnI and trnA genes. Digestion of untransformed
wild type (WT) plant DNA with AflIII showed 4.2-kb fragment
after hybridizing with 32P-labeled trnI-trnA flanking probe, and
transplastomic CTB-MBP lines showed only the 6.7-kb fragment,
536
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confirming homoplasmy and site-specific integration of transgene (Figure 1b). Immunoblots probed with CTB (Figure 1c)
and MBP (Figure 1d) antibody showed ~28.5-kDa fusion protein monomer, dimer at ~57 kDa, and trimer at ~86 kDa in CTBMBP transplasomic lines. Fresh leaves expressed up to 2% of total
leaf protein, but a 17-fold enhanced antigen concentration was
achieved by lyophilization of the plant material (Figure 1c). Equal
loading of protein showed a significant difference in accumulation
of CTB-MBP between fresh and lyophilized materials (Figure 1e).
Moreover, immunoblots probed with CTB antibody showed that
lyophilized material maintained stability at room temperature
(RT) and protection from degradation over 7 months of storage
(Figure 1f).
The functionality of CTB-MBP fusion protein was evaluated
by GM1 enzyme-linked immunosorbent assay (ELISA), where the
ability of CTB to bind to GM1 receptors depends on its pentameric
form. GM1 binding assay showed that pentamers of fresh weight
and lyophilized CTB-MBP were formed, confirming proper folding and disulfide bond formation (Figure 1h). Non-reducing
native polyacrylamide gel electrophoresis immunoblots probed
with CTB antibody further confirmed the formation of the pentameric structure (Figure 1g) within transgenic chloroplasts, attesting functionality of CTB-MBP for in vivo studies. Lyophilization
process preserved the folding and disulfide bonds of CTB-MBP
protein even after prolonged storage at RT (Figure 1f).

Oral delivery of bioencapsulated CTB-GFP and
CTB-MBP across BBB/BRB
Oral gavage of CTB-green fluorescent protein (GFP) bioencapsulated plant cells created in a previous study24 showed GFP fluorescence in mouse circulation system. Healthy C57BL/6J mice showed
uptake of GFP in the sera and different organs (Figure 2a) measured by using GFP ELISA kit. After 2 hours of gavage, 364 pg/ml
of GFP was observed in the sera, and a lot more in other organs,
showing very efficient and rapid delivery into the circulatory system. The highest GFP retention (2,512 pg/mg) was observed in the
liver, followed by the lung (1,720 pg/mg), the kidney (1,446 pg/mg),
and the heart (509 pg/mg). A concentration of 348 and 945 pg/mg
of GFP uptake in the brain and retinal tissue of mice, sacrificed after
5 hours of the last gavage, shows delivery of GFP across the BBB and
BRB in healthy mice having fully intact BBB/BRB. Healthy mice
orally gavaged with bioencapsulated CTB-MBP plant leaf material
for 3 consecutive days showed MBP deposits in the hippocampus
region when evaluated by immunofluorescence on fixing brain tissue overnight (Figure 2b). WT and triple transgenic (3×Tg) AD
mice fed with CTB-MBP also showed increased MBP levels in different regions of the brain (Figure 2c–f), confirming efficient transmucosal delivery of bioencapsulated proteins across the BBB. Data
for absolute values are provided along with percentage of respective
control samples. The absolute fluorescence intensity values of MBP
from WT mouse brain are different from 3×TgAD mice because
they are different mouse strains and different in their age. In addition, these experiments were done differently: 3 consecutive days
of oral gavage of 6-week-old C57BL/6J mice with CTB-MBP, and
sections were freshly cut and immune stained. On the other hand,
15-month-old 3×TgAD mice were gavaged for 3 months, and sections tissues were stored in a freezer for evaluation.
www.moleculartherapy.org vol. 22 no. 3 mar. 2014

© The American Society of Gene & Cell Therapy

a

Drug Delivery Across Blood Brain/Retinal Barriers

b

WT

16S

trnI

trnA

1

2

6.7 kb

4.2 kb

Afl III

WT

Afl III

Transformed
16S

Prrn

trnI

aadA1

trnA

3′psbA

6.7 kb

Afl III
1 2 3

Afl III

d

4 5 6

200

1

e

2

200

100
75
50
37

150
100
75
50
37

1

3

h

150
100
75
50
37
25
20
15
10
CTB Ab

3

4

5 6

10
CTB Ab
6

i

3.5

5

3
2.5
2
1.5
1
0.5
0

2

CTB Ab

4
Absorbance (450 nm)

200

MBP Ab

1

37
25

15
10

10
CTB Ab
2

f

2

25
20

15

15
10

1

150
100
75
50
37

25
20

25
20

4.2 kb

CTB-MBP (mg/g)

c

g

CTB MBP

5′psbA

4
3
2
1
0

1

2

3

4

1

2

Figure 1 Characterization of CTB-MBP transplastomic lines. (a) Schematic representation of wild type (WT) and transformed tobacco chloroplast
genome. (b) Digestion with AflIII yields 4.2 and 6.7 kb fragments in WT and transplastomic lines,1,2 respectively in Southern blot. Western blots of
CTB-MBP expression in fresh (F) and lyophilized (L) transgenic plant extracts. (c) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) with anti-CTB antibody (Ab). Lanes 1, 2, and 3—12.5, 25, and 37.5 ng purified CTB standard; lanes 4, 5, and 6—20 µg of crude extract F, L,
and WT. (d) SDS-PAGE with anti-MBP Ab. Lanes 1 and 2—20 µg of F and L, respectively. (e) SDS-PAGE with anti-CTB Ab for normalization of F and
L transgenic plant proteins. In lanes 1 and 2, equal quantities (100 mg) of F and L samples were ground in 300 µl of extraction. (f) Western blot
analysis showing long-term stability of CTB-MBP (L) after storage at room temperature (RT) for 7 months. Lanes 1, 2, 3, 4, and 5 (November, January,
March, April, and May)—20 µg of L stored at RT for different durations, lane 6—12.5 ng CTB standard. (g) Native PAGE probed with anti-CTB Ab.
Lane 1—37.5 ng purified CTB standard; lanes 2 and 3—2 µg of F and L, respectively. (h) GM1 enzyme-linked immunosorbent assay of purified CTB
(25 ng), transgenic CTB-MBP protein in 20 µg of F, L, and WT extracts in lanes 1, 2, 3, and 4 respectively. (i) Quantification of CTB-MBP protein (mg
of protein/g of total leaf) in F and L plant extracts in lanes 1 and 2, respectively. CTB, cholera toxin B subunit; MBP, myelin basic protein.

Role of CTB in delivery of GFP into M17 human
neuroblastoma cells
M17 human neuroblastoma cells31 incubated with GFP or CTBGFP showed GFP fluorescence on the surface or within cells only
with CTB-GFP and not with GFP alone (Figure 3a). The absence
of GFP within neuroblastoma cells shows the requirement for CTB
as a carrier to deliver the fused protein across CNS cells. Inability
of controls, particularly incubation with GFP without CTB fusion,
to bind to M17 cells confirms that human neuroblastoma cells can
uptake only the CTB-GFP fusion protein.
Ex vivo reduction of amyloid levels in 3×TgAD mice
brains by CTB-MBP
Ex vivo studies of Thioflavin S (ThS)–stained brain sections
from 24-month-old 3×TgAD mice showed reduction in amyloid
plaques in hippocampus and cortex in a concentration-dependent
manner when incubated with chloroplast-derived CTB-MBP
Molecular Therapy vol. 22 no. 3 mar. 2014

(Figure 4a). Reduction in ThS fluorescence up to 60% was
detected after 2 days of incubation with different concentrations
of CTB-MBP plant-derived protein, in adjacent brain sections
(Figure 4b). Incubations with protein extract from WT plants,
phosphate-buffered saline (PBS), or purified CTB under identical
conditions did not show any effects in ThS intensity, suggesting
that CTB-MBP, at an optimal concentration of 50 µg/section, is
able to perform Aβ degrading enzymatic activity,27 thereby reducing their ThS fluorescence (Figure 4b). Data shown are mean ±
SD of values obtained from 7 adjacent sections and evaluated
from a total of 63 fluorescence images, confirming reproducibility
of this observation.

Ex vivo reduction of amyloid levels in postmortem
human AD brains by CTB-MBP
Ex vivo studies of ThS-stained brain sections of postmortem
human brain tissues from advanced AD patients were conducted
537
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with incubation of 50 µg/section CTB-MBP chloroplast expressed
protein (Figure 5a), a working concentration of MBP from ex
vivo mice brain studies. Incubation with CTB-MBP showed up
to 47% ThS fluorescence reduction of stained amyloid plaques in
inferior parietal cortex of human brain sections (Figure 5b) when
compared with WT plant extract, indicating that MBP through its
serine proteinase activity is able to degrade amyloid aggregates,
thereby reducing their ThS fluorescence (Figure 5b) in human
brain tissues. Data shown are mean ± SD of values obtained from
5 sections of 5 different human AD postmortem brains and evaluated from a total of 10 fluorescence images. Although only limited
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Figure 2 Evaluation of green fluorescent protein (GFP) and myelin basic protein (MBP) levels on oral delivery of plant cells expressing CTB
fusion proteins. (a) GFP levels in different organs following oral gavage of CTB-GFP leaf material. Six weeks old mice were orally fed with CTB-GFP
transgenic tobacco leaf suspension (~ 200 mg/mouse/day; n = 5) for 3 consecutive days. Blood samples were collected at 2 and 5 hours after the last
gavage at which, mice were sacrificed and tissue samples were collected. GFP concentration in tissues was measured by enzyme-linked immunosorbent
assay. (b) Immunofluorescent detection of MBP in different regions of the C57Bl/6J mouse brain fed with CTB-MPB or control untransformed (wild
type (WT)) leaf materials. WT C57 mice were orally gavaged with CTB-MBP or WT leaf materials for 3 consecutive days. Tissues were harvested 5 hours
after the last gavage and fixed overnight in 4% paraformaldehyde. Cryostat brain sections at the level of hippocampus were cut and mounted on
Superfrost Plus slides. The sections were incubated in blocking solution (5% bovine serum albumin (BSA) + 0.3% Triton X-100 in phosphate-buffered
saline (PBS)) for 1 hour, followed by incubation with rabbit anti-MBP polyclonal antibody 1:100 (ab 65988; Abcam), which recognizes both human and
endogenous mouse MBP, overnight at 4 °C. The sections were then incubated with an anti-rabbit immunoglobulin G secondary antibody conjugated
to Alexa 594 (Molecular Probes/Invitrogen) for 1 hour at RT. Sections were washed in PBS containing the nuclear counterstain DAPI (4′,6 diamidino-2phenylindole) and mounted in Dako mounting media (bar = 50 µm). I–VI: six layers of cortex. cc: corpus callosum. (c,d) Quantification of MBP levels
in different regions of C57Bl/6J mouse brain fed with CTB-MPB or control WT leaf materials. Immunofluorescence images were taken from fields within
motor cortex (layers 1–3 and layers 4–6) and in CA1 and CA3 regions of hippocampus with a 40× objective and constant exposure times on a Keyence
confocal microscope. Threshold for images were set manually using NIH Image J software, and fluorescence intensity was determined by using the
measure module. Fluorescent intensity values in CTB-MBP–fed mice were normalized to the control (WT leaf fed) levels. n = 5. (e,f) Quantification
of MBP levels in different regions of triple transgenic Alzheimer’s disease (3×TgAD) mice brain fed with CTB-MPB or control WT leaf materials for
3 months. The values on y-axis of c and e represent the percentage of the control. n = 8. P < 0.01 (CTB-MBP versus WT) for all regions measured. AD,
Alzheimer’s disease; CTB, cholera toxin B subunit; NIH, National Institutes of Health.
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Figure 3 Evaluation of green fluorescent protein (GFP) in M17 human neuroblastoma cells incubated with GFP or CTB-GFP by fluorescence
microscopy. CTB-GFP was partially purified from transgenic leaf extracts. M17 cells were incubated with 23.3 nmol/l of CTB alone or WT leaf extracts
or purified GFP or CTB-GFP for 24 hours and processed for GFP fluorescence in parallel. Images of live nonfixed cells were taken at an original magnification of ×20 using GFP filter for 4 seconds using Nikon Eclipse, TE2000-E fluorescence microscope. Representative images are shown in the bottom
panel. Representative images of intracellular (arrowhead) GFP fluorescence in M17 cells treated with CTB-GFP are also shown. CTB, cholera toxin B
subunit; PBS, phosphate-buffered saline.

at the start of this study. Adjacent cortex and hippocampus sections of control and CTB-MBP–treated mice stained with the antiβ-amyloid antibody (Figure 6a, red) or ThS (Figure 6b, green)
were examined and quantified as described in the Methods section.
Most plaques were found in the hippocampus region, particularly
dentate gyrus (DG), Cornu Ammonis (CA)1, and CA3 sites, from
where they started diffusing to the cortex as AD progressed. Aβ
level reduction up to 67.3 and 33.4% was observed in hippocampus and cortex, respectively (Figure 6c), through immunostaining
with anti-Aβ antibody on oral delivery of CTB-MBP. Data shown
are mean ± SD of values obtained from 5 adjacent sections from
each mouse and evaluated from a total of 120 fluorescence images.

Evaluation of amyloid levels in vivo in 3×TgAD mice
brain
ThS-stained plaque number and fluorescence intensity was
also reduced up to 70 and 40%, respectively (Figure 7a), quite
Molecular Therapy vol. 22 no. 3 mar. 2014

consistent across eight groups of age-matched 3×TgAD mice on
oral delivery of CTB-MBP leaf material. Data were obtained as
described before. Aβ peptide is produced in the brain where it
normally remains in a soluble state, and its function is still largely
unknown. Accumulation, aggregation, and deposition of Aβ peptides are pathological hallmarks in the AD brains and are found in
the insoluble state.32
Therefore, we investigated the effect of MBP on Aβ-42 levels
from soluble and insoluble fractions of protein extracts isolated
from hippocampus of CTB-MBP–fed and control 3×TgAD mice
by both ELISA and western blotting using anti-Aβ42–specific antibody. The high molecular weight Aβ-42 aggregates were reduced
in the insoluble fractions of hippocampus with corresponding
increase of Aβ-42 in the soluble fraction in mice fed with bioencapsulated CTB-MBP, when compared with unfed or WT fed
mice (Figure 7b,c). The ratio of Aβ-42 levels in the insoluble
versus soluble fractions of proteins isolated from hippocampus,
539
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Figure 4 Ex vivo evaluation of amyloid plaque load in triple transgenic Alzheimer’s disease (3×TgAD) mouse brain tissue sections. (a)
Sagittal serial sections of brains from 3×TgAD mice were incubated with
25 or 50 µg recombinant CTB-MBP protein purified from transgenic leaf
extracts or 25 or 50 µg commercially available purified CTB for 2 days
and then stained with 0.02% thioflavin S (ThS) solution to visualize the
central dense core of compact amyloid (green) by fluorescence microscopy. As controls, adjacent sections were incubated with 25 or 50 µg
of wild type (WT) leaf extracts or saline alone and processed for ThS
staining in parallel. Sections including the hippocampus and cortex of
representative 24-month-old 3×TgAD mice (bar = 20 µm) are shown.
(b) Quantification of the relative amounts of amyloid plaque load in
the ThS-stained sections after incubation with the indicated proteins or
saline alone as described in (a). The mean plaque counts in the DG,
CA1, and CA3 hippocampal and cortical regions per section (in cortex,
mantle, and pallium regions) were determined with NIS Elements for
Advanced Research. The values in the histogram represent the mean ±
SD> n = 63; *P < 0.05 (single factor analysis of variance) relative to control. AD, Alzheimer’s disease; CTB, cholera toxin B subunit; MBP, myelin
basic protein.

measured by ELISA, showed a 2.7-fold decrease (Figure 7d) in
CTB-MBP–fed mice when compared with respective controls.

Reduction of amyloid level and protection of retinal
ganglion cells in mouse retina after oral delivery of
bioencapsulated CTB-MBP
In addition to cognitive and behavioral deficits, visual abnormalities are also frequently seen in AD patients. Therefore, we
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Figure 5 Ex vivo evaluation of amyloid plaque load in postmortem
Alzheimer’s disease (AD) human brain tissue sections. (a) Sections of
the parietal cortex from human AD were incubated with 50 µg recombinant CTB-MBP protein partially purified from transgenic leaf extracts
or 50 µg of partially purified wild type (WT) for 2 days and then stained
with 0.02% thioflavin S (ThS) solution to visualize the central dense core
of compact amyloid (green) and with DAPI (4′,6 diamidino-2-phenylindole) to identify cell nuclei (blue) by fluorescence microscopy. (Bar =
20 µm). (b) Quantification of the relative amounts of amyloid plaque
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determined with NIS Elements for Advanced Research. The values in the
histogram represent the mean ± SD> n = 8; *P < 0.001 (single factor
analysis of variance) relative to control. CTB, cholera toxin B subunit;
MBP, myelin basic protein.

examined the 3×TgAD mouse eyes from animals that received
oral gavage of bioencapsulated CTB-MBP plant leaf material for
3 months as well as eyes from age-matched untreated 3×TgAD
and healthy mice. Amyloid deposit in the retina was evaluated by
immunofluorescence using a biotin-labeled monoclonal antibody
specific for Aβ1–42. Intense staining for Aβ1–42 was detected in
the inner retina, primarily in the RGC layer in 3×TgAD mice, but
almost undetectable in healthy and 3×TgAD mice fed with CTBMBP leaf materials (Figure 8a–f). The retinal level of Aβ1–42
was also evaluated by western blotting using the same antibody,
and there was more than 60% reduction in the retinae from CTBMBP–fed mice, especially among high molecular weight peptide
aggregates (Figure 8g,h). The retinae of 3×TgAD mice also showed
marked loss of RGCs and increase of apoptotic cells detected by
TUNEL (terminal dUTP nick end labeling) assay compared with
age-matched control mice (Figure 8i–m). Amyloid deposit and
apoptotic cells are significantly reduced in mice fed with CTBMBP, and the loss of RGCs was restored.

DISCUSSION

Results of investigations show efficient in vivo oral delivery of
chloroplast expressed CTB fusion proteins across BBB and BRB.
The native confirmation of CTB pentamers facilitates binding to
the intestinal GM1 receptors and releases the fused protein to the
circulatory system when orally administered. The mechanism of
www.moleculartherapy.org vol. 22 no. 3 mar. 2014
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Figure 6 In vivo evaluation of amyloid plaque load on orally delivered CTB-MBP in triple transgenic Alzheimer’s disease (3×TgAD) mice. (a,b)
Representative images of the cortical and hippocampal brain sections of 12- to 14-month old 3×TgAD mice fed with either recombinant CTB-MBP
bioencapsulated in plant cells (31.2 µg/300 µl/day; n = 8 mice), wild type (WT) leaf extracts (300 µl/day; n = 4 mice), or unfed (n = 4 mice). Sections
were stained for amyloid plaques with either anti-Aβ antibody 2454 (red fluorescence; a) or thioflavin S (ThS) (green fluorescence; b) and with DAPI
((4′,6 diamidino-2-phenylindole) blue) to label cell nuclei. Bar = (i) hippocampus 100 µm and (ii) 10µm at different magnifications and (iii) cortex
10 µm). (c) Quantification of the relative amounts of amyloid plaque load in the anti-Aβ and ThS-stained sections from the animals fed with CTBMBP or WT protein extracts as described in (a,b). The mean plaque counts in the DG, CA1, and CA3 hippocampal and mantle and pallium cortical
regions per section were determined with NIS Elements for Advanced Research. The values in the histogram represent the mean ± SD> n= 63; single
factor analysis of variance *P < 0.05 for cortex, **P < 0.01 for hippocampus when compared with mice treated with WT leaf extracts and unfed. AD,
Alzheimer’s disease; CTB, cholera toxin B subunit; MBP, myelin basic protein.

CTB binding to GM1 is well known.33 A recent study has shown
that polymeric nanoparticles coated with GM1 binding peptide
promoted transcytosis across the BBB.34 Presence of a voltageindependent GM1 associated with a Ca2+ channel has also been
observed using CTB-induced Ca2+ influx in neuroblastoma cells.31
Direct evidence for crossing of BBB or BRB by CTB fusion proteins has been provided in our study by: (i) entry of CTB-GFP
but not of GFP into neuroblastoma cells; (ii) presence of GFP in
brain tissues on oral delivery of CTB-GFP; (iii) increase in MBP
in brain tissues on oral delivery of CTB-MBP; (iv) decrease in
amyloid plaques in 3×TgAD mouse brain slices in ex vivo studies with CTB-MBP incubation with ThS staining; (v) decrease
in individual amyloid plaques in human Alzheimer’s brain slices
in ex vivo studies with CTB-MBP incubation with ThS staining;
(vi) decrease in amyloid plaques in 3×TgAd mouse brain on oral
delivery of CTB-MBP bioencapsulated in plant cells (ThS staining and immunofluorescence images and quantitation); and (vii)
Molecular Therapy vol. 22 no. 3 mar. 2014

removal of Aβ plaques in 3×TgAd mouse retina on oral delivery
of CTB-MBP. All these independent lines of investigations provide direct evidence for CTB fusion proteins crossing BBB and
BRB, the key finding of this research project.
When compared with significant GFP delivery observed in the
brains of healthy mice with intact BBB, the amount of CTB fused
protein delivered across impaired BBB in AD brains is anticipated
to increase further. BBB impairment is associated with more rapid
progression in AD.35 Previous literature27,28 has shown that MBP
inhibited Aβ fibril formation, where binding site for Aβ is situated
at N-terminal 64 amino acids of MBP. Inhibition of fibril assembly
by N-terminal domain of MBP was observed. MBP may directly
degrade Aβ peptide aggregates/plaques36 due to its intrinsic proteinase activity as also shown in our ex vivo studies. MBP may
prevent Aβ peptide aggregation and plaque formation by direct
binding of MBP through its N-terminal domain.27 It is likely that
both mechanisms may take place, because a substantial fraction
541
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Figure 7 Quantitative evaluation of amyloid levels in triple transgenic Alzheimer’s disease (3×TgAD) mice on CTB-MBP oral delivery. (a)
Eight groups of age-matched 3×TgAD mice fed with CTB-MBP showed consistent reduction in thioflavin S (ThS) intensity stained amyloid plaques,
***P < 0.0001, evaluation of (b–d) total Aβ(40/42) levels were measured by immunoblotting using anti-Aβ42 antibody, 12F4 (b,c) and enzyme-linked
immunosorbent assay (d). *P < 0.05. AD, Alzheimer’s disease; CTB, cholera toxin B subunit; MBP, myelin basic protein; WT, wild type.

of the fusion protein will likely be cleaved in the circulation, as
well as at target cells on uptake. Our data show increased MBP
levels in different regions of the brain from animals fed with CTBMBP; however, this detection method is not sensitive enough to
differentiate internalized versus extracellular MBP protein. Our
results clearly demonstrate the uptake of CTB-MBP into different
regions of the brain via oral delivery of the protein bioencapsulated in plant cells. Future studies will be needed to fully understand molecular and cellular mechanism of this process.
It is well known that ThS staining is specific for
AB-immunoreactive deposits in the brain, and computer algorithms to detect such neurons have been developed.37 This study
also shows significant reduction of ThS-stained amyloid deposits
in advanced human AD post mortem brain sections, when incubated with CTB-MBP. However in each brain section, obtained
from different individuals suffering with AD at an advanced stage,
542

consistent reduction of ThS staining was observed on incubation
with chloroplast-derived CTB-MBP. Similarly, we observed significant concentration-dependent degradation and/or reduction
of amyloid levels in the brains of old 3×TgAD mice on CTB-MBP
incubation. We observed that 3×TgAD mice brain showed a significant decrease of amyloid levels when fed with CTB-MBP, particularly in dentate gyrus, CA1 and CA3 regions of hippocampus,
and in cortical brain regions, which are known to carry the most
amyloid burden in transgenic AD mice as well as in human AD.38
Moreover, ThS-positive amyloid deposits were observed in the
areas of anti-amyloid immunoreactivity by staining hippocampus in adjacent brain sections in in vivo studies with anti-amyloid
antibody and ThS. Moreover, reduction in Aβ plaque number and
ThS intensity was uniform in CTB-MBP–fed mice. Histological
analyses confirm quantitative as well as qualitative reduction of
Aβ accumulation through MBP in 3×TgAD mice and human AD.
www.moleculartherapy.org vol. 22 no. 3 mar. 2014
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Figure 8 Evaluation of Aβ1–42 and inner retinal cells in triple transgenic Alzheimer’s disease (3×TgAD) mice on oral delivery of CTB-MBP.
(a,c,e) The Aβ1–42 was detected by immunofluorescence using a biotin-conjugated monoclonal antibody to Aβ1-42 followed by Texas RedStreptavidin counterstained with DAPI (4′,6 diamidino-2-phenylindole)(b,d,f). (g) Western blot of retinal proteins isolated from untreated and CTBMBP fed 3×TgAD mice using antibody against Aβ1–42. (h) Quantitative analysis of western blot data (n = 4). The protein levels were normalized to
those of actin, and the densitometric value from each of the treated eyes is expressed as a percentage relative to the untreated eyes, *P < 0.01. (i–k)
Representative micrographs of retinal cross-sections from age-matched (i) healthy control, (j) untreated 3×TgAD, and (k) CTB-MBP–fed 3×TgAD
mice. (l) Quantitative measurement of cell density in the retinal ganglion cell (RGC) layer. (m) Quantitative measurement of apoptotic cells detected
by TUNEL (terminal dUTP nick end labeling) assay. *P < 0.01 (versus untreated 3×TgAD eyes; n = 4). Bar = 20 µm. AD, Alzheimer’s disease; CTB, cholera toxin B subunit; INL, inner nuclear layer; IPL, inner plexiform layer; MBP, myelin basic protein; ONL, outer nuclear layer; OPL, outer plexiform layer.

Furthermore, biochemical analyses and quantitation of Aβ42
levels show a 2.7-fold decrease in the ratio of insoluble versus soluble Aβ42 protein levels in the hippocampus of 3×TgAD mice,
demonstrating reduced insoluble aggregates in CTB-MBP–fed
mice when compared with control analyzed by both immunoblotting and ELISA. In healthy brains, at normal physiological states,
Aβ exists as a low molecular weight protein in the soluble form
that regulates synaptic functions in the neuronal metabolism.39
Therefore, soluble Aβ is essential for synaptic plasticity and neuronal survival. The clearance of amyloid load in this study warrants behavioral studies. However, this should be done in younger
Molecular Therapy vol. 22 no. 3 mar. 2014

mice at the early onset of AD rather than in highly advanced
stages of AD used in this study. Although a number of studies
correlate accumulation of Aβ plaques to dementia, a few recent
studies have questioned such direct correlation because one-third
of people with plaque in their brains never show cognitive decline.
However, a recent study40 has resolved this controversy by demonstrating that memory decline is associated with spatial patterns of
amyloid deposition rather than total amyloid burden.
Moreover, we also found increased accumulation of Aβ42
levels, loss of retinal ganglion cells, and increased number of
apoptotic cells in the retina of 3×TgAD mice when compared
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with age-matched healthy control mice. These retinal pathologies are significantly reduced in mice fed with chloroplast-derived
CTB-MBP, suggesting that orally administrated CTB-MBP can
be delivered to retina crossing BRB, presumably by a similar
mechanism mediated by GM1 receptors discussed above. These
results demonstrate that this strategy could be used to deliver
other therapeutic proteins for retinal diseases. It is surprising that
CTB-MBP treatment prevented the loss of RGCs. Because the
treatments started in older mice (13–15 months old) for 3 months
and RGCs do not regenerate, it is possible that the loss of RGCs is
more prominent in older mice. Alternatively, although not mutually exclusive, the density of RGCs was counted from hematoxylin
and eosin–stained sections, which may have included other cell
types in this layer, such as astrocytes, pericytes, and endothelial
cells, CTB-MBP treatment may also prevent the loss of these cell
types, or may promote their proliferation. Further studies are
needed to address these possibilities.
Active and passive immunotherapies have been reported to
target Aβ in clinical studies41 through immunization, but recent
disappointment with bapineuzumab, a humanized anti-amyloid antibody in clinical trial III calls for alternative strategy for
Alzheimer’s drugs and therapies. Restricted delivery of monoclonal antibody to the brain, significantly contributed to the
failure of this study and other studies. Along with an efficient
oral delivery of antigen through plant bioencapsulation, chloroplast transformation method offers an inexpensive production,
storage, and transportation of biopharmaceutically important
proteins.23,42 Lyophilization of plant cells increased CTB-MBP
concentration, facilitating storage of capsules at RT for several
months without any degradation of therapeutic protein.43,44 CTB
is an US Food and Drug Administration–approved antigen,45 and
MBP is naturally in circulation in the human sera. Side effects of
CTB have been already investigated for higher doses than used
in this study. CTB fused autoantigens are not immunogenic but
suppress formation of antibodies.46–48 Plant cells are routinely
consumed, and so, bioencapsulation of CTB-MBP within plant
cells should not cause toxicity concerns. Recently, the US Food
and Drug Administration approved a carrot cell–based system for
production of the first human therapeutic protein.22 Therefore,
receptor-mediated oral delivery of therapeutic proteins to the circulatory system and across BBB and BRB, barriers that protect the
brain and retina, opens the door for a novel concept and further
advances in human clinical studies.

MATERIALS AND METHODS
Vector construction, regeneration, and confirmation of transgene integration. Fusion construct was made with CTB and human MBP, which

were separated by glycine–proline–glycine–proline hinge to avoid steric
hindrance. In addition, a furin cleavage site was introduced between the
two proteins. The pLD-CTB-MBP vector was created, and chloroplast
transformation system was used to regenerate CTB-MBP transplastomic
plant lines.30 Plant DNA isolation was followed by restriction digestion
with AflIII and Southern blot to confirm integration of transgene and
homoplasmy using hybridization with [32P]α[dCTP]-labeled chloroplast
flanking sequence probe containing trnI-trnA genes.30
Expression and preparation of frozen and lyophilized plant material.

Extracted proteins from plants at greenhouse were separated on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis gels as described before.43
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The CTB-MBP fusion protein was also probed with rabbit anti-human MBP
primary monoclonal antibody (1:1,000; Abcam, Cambridge, MA) followed
by goat anti-rabbit immunoglobulin G-horseradish peroxidase–conjugated
secondary antibody (1:4,000; Southern Biotech, Birmingham, AL). CTBMBP material was lyophilized, and immunoblots and GM1 assays were
performed as described before.43 Native polyacrylamide gel electrophoresis
was carried for detection of pentameric state of fusion protein as detailed
elsewhere.47 For oral delivery, plant material was prepared by adding 4 and
1 ml of PBS to 500 mg of lyophilized CTB-MBP and 100 mg of fresh weight
CTB-GFP, respectively and stored on ice right until oral gavage.
Mice and oral delivery experiments. For oral delivery of CTB-GFP,

6-week-old healthy C57BL/6J mice (The Jackson Laboratory, Bar Harbor,
ME) were used. Mice (n = 5) were orally gavaged with bioencapsulated
CTB-GFP (~200 mg/mouse/day) for 3 consecutive days. For oral delivery of CTB-MBP, 13- to 15-month old (at the start of study, 7 male and 7
female) 3×TgAD mice,49 purchased from the National Institute of Aging,
were housed in University of Central Florida animal facility under controlled humidity and temperature conditions. The lyophilized leaf material
for oral gavage at a dose of 31.2 µg/300 µl/day of either plant bioencapsulated CTB-MBP (n = 10) or WT (n = 4) was delivered three times a week,
for 3 months. A set of mice (n = 4) were kept unfed.
Preparation of tissues. On the day of sacrifice, all mice were perfused

with saline, and brains were dissected. Right hemisphere of the brain from
3×TgAD mice was prepared for histological analysis in 4% paraformaldehyde and cryoprotected in 30% sucrose overnight, whereas the three brain
regions—cerebellum, hippocampus, and cortex—were dissected from left
hemisphere for Aβ measurements in biochemical analyses. For GFP measurements in healthy mice, blood samples were collected at 2 and 5 hours of
last gavage at which mice were sacrificed, and tissue samples were collected
for protein isolation. For oral delivery of CTB-MBP in C57 mice, tissues
were harvested 5 hours after the last gavage and fixed overnight in 4% paraformaldehyde. Cryostat brain sections at the level of hippocampus were cut
and mounted on Superfrost Plus slides (Thermo Fisher Scientific, Waltham,
MA). The sections were incubated in blocking solution (5% bovine serum
albumin+ 0.3% Triton X-100 in PBS) for 1 hour, followed by incubation
with rabbit anti-MBP polyclonal antibody 1:100 (ab 65988, Abcam), which
recognizes both human and endogenous mouse MBP, overnight at 4 °C.
The sections were then incubated with an anti-rabbit immunoglobulin
G secondary antibody conjugated to Alexa 594 (Molecular Probes/Life
Technologies, Grand Island, NY/Invitrogen, Camarillo, CA) for 1 hour at
RT. Sections were washed in PBS containing the nuclear counterstain DAPI
(4′,6 diamidino-2-phenylindole) and mounted in Dako mounting media
(bar = 50 µm; Dako North America, Carpinteria, CA). For ex vivo studies,
AD mice brain tissues were obtained from the National Institute of Aging
and AD human brain tissues were obtained as described before.49

ELISA and immunoblotting from mouse brain tissue. Dissected hippo-

campal tissues from 3×TgAD mice were homogenized in radio-immunoprecipitation assay (RIPA) buffer. The homogenate was ultracentrifuged at
350,000g for 20 minutes at 4 °C. Supernatant was collected (soluble fraction), and pellet was dissolved in 2% sodium dodecyl sulfate/PBS (insoluble fraction). Protein concentration was determined using Bicinchoninic
Acid Protein Assay kit (Pierce, Rockford, IL). Protein samples (15 µg) were
separated on 10–20% TrisTricine gels (cat. # 456– 3114; BioRad, Hercules,
CA) and transferred to 0.2-mm nitrocellulose membranes. Blots were
probed with β amyloid 1–42 (12F4) monoclonal antibody (biotin labeled)
(cat. # SIG-39144; COVANCE, Princeton, NJ). Blots were reprobed with
anti β-actin monoclonal antibody (A2228; Sigma-Aldrich, St. Louis, MO)
as a loading control. Visualization of specific bands was performed using
Odyssey Infrared Fluorescence Imaging System (Odyssey; Li-Cor, Lincoln,
NE). For ELISA, both soluble and insoluble fractions were assayed for
Aβ42 using commercial ELISA kit (Invitrogen Human Ab42 ELISA kit cat
# KHB3441). GFP concentration in tissues was measured by GFP ELISA
www.moleculartherapy.org vol. 22 no. 3 mar. 2014
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kit (AKR121; Cell Biolab, San Diego, CA). Results were compiled using
SoftMax Pro software (Molecular Devices LLC, Sunnyvale, CA).
Immunohistochemistry and ThS staining. Brain cryosections (8-µm
thick) from CTB-MBP orally delivered 3×TgAD mice were obtained using
microtome slicing system (Microm HM 505N; Thermo Fisher Scientific).
Adjacent sections were exposed for 60 minutes to PBS containing 0.1%
Triton X-100 (Sigma-Aldrich) and 5% normal goat serum (Invitrogen) to
block nonspecific binding, followed by incubation with primary antibody,
polyclonal anti-amyloid β (1:200 Cell Signaling Technology, Boston, MA;
cat. # 2454 overnight at 4 °C. To test for nonspecific staining by secondary antibody, additional slides were processed in similar fashion with
primary antibody being excluded. All slides were then rinsed for 1 hour
at RT in several changes of PBS and incubated in the dark for 1 hour at
RT in PBS containing 5% normal goat serum and fluorescent secondary
antibody, Alexa Fluor 568-conjugated immunoglobulin G (1:200). After
counterstaining with Hoescht 33342 (Invitrogen), images were acquired
by Nikon Eclipse TE2000-E fluorescence microscope (Nikon Instruments,
Melville, NY) and processed by NIS Elements for Advanced Research,
with the input levels adjusted to span the range of acquired signal intensities. For each mouse, five adjacent sections were selected, and from each
section, three random fields were analyzed. Total area of pixel intensity
was measured with the automated measurement tools in NIS Elements
software. The total intensity was averaged and expressed as normalized,
corrected values. Statistical analysis for the data was analyzed by single factor analysis of variance. Similarly, following PBS rehydration, adjacent five
sections were stained with 0.02% ThS (Sigma-Aldrich) in 70% ethanol for
8 minutes. Slides were then rinsed in 50–80% ethanol and distilled water,
respectively and cover slipped with DAPI solution for acquiring images.
For ex vivo brains from 24-month-old 3×TgAD mice, 7-µm cryostat
sections were mounted on slides. Seven adjacent sections were incubated
with 25 or 50 µg per section of 33% purified CTB-MBP plant protein in
PBS. Commercial CTB alone, bovine serum albumin, and WT plant protein
were also used as controls. After 2 days of incubation at 37 °C, sections were
stained with ThS,27,37 imaged, and quantified as described above. For each
of three ex vivo brains, seven adjacent sections were selected, and from
each section, three random fields were analyzed. Threshold intensity was
based on the intensity of background staining in control sections. The
selected threshold was held constant across all experimental sections. Ex
vivo postmortem human brain tissues from AD were deparaffinized and
rehydrated to ensure optimal staining. The slides were passed through
xylene followed by graded washes of xylene and ethanol, with a final wash
of pure water. Brain sections were incubated with 50 µg/section of 33%
purified CTB-MBP or WT plant material. After 2 days of incubation at 37
°C, sections were stained with ThS and DAPI to acquire images as described
above. For each of the five AD human brain sections from different
individuals, two random fields were analyzed and quantified.
Eye tissue processing, immunofluorescence, and quantification. For
western blot analysis, fresh retina was dissected and processed the same
way as described for brain tissues. For frozen sections, enucleated eyes
were fixed in 4% paraformaldehyde at 4 °C overnight. Eyecups were cryoprotected in 30% sucrose/PBS for several hours or overnight prior to quick
freezing in optical cutting temperature compound. Then 12-µm thick sections were cut at 20–22 °C.
A biotin-labeled monoclonal antibody against Aβ-42 (1:100,
COVANCE cat. # SIG-39144) was used. Sections were permeabilized
with 1% Triton X-100 for 10 minutes, followed by blocking with
5% bovine serum albumin. Sections were incubated in the primary
antibody overnight at 4 °C and washed with PBS. Texas Red conjugated
streptavidin was used (1:200; Vector Laboratories, Burlingame, CA) as
secondary antibody. Slides were cover slipped using VECTASHIELD
(Vector Laboratories), and antibody labeling was examined with a Zeiss
(AxioVision Carl Zeiss Micro Imaging, Thornwood, NY) microscope
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equipped with epifluorescence illumination and a high-resolution digital
camera. For quantitative measurement of inner retinal neuron density,
frozen sections were counterstained with hematoxylin and eosin, the
number of nuclei in the RGC layer was counted from at least 10 sections
from each eye, 4 eyes from each group (untreated, CTB-MBP–fed
3×TgAD, and age-matched healthy control mice). To detect apoptotic
cells, an In Situ Cell Death Detection Kit based on TUNEL technology
(Roche Applied Science, Indianapolis, IN) was used.
Cell culture studies with bioencapsulated CTB-GFP. M17 human neuroblastoma cells were cultured in Opti-MEM I Reduced Serum Media (Invitrogen/
Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin in a 37 °C humidified incubator with 5% CO2. Treatment media consisted of only Opti-MEM reduced
serum media (2% serum) excluding both fetal bovine serum and penicillin/
streptomycin. Treatments were performed at ~70% confluency. Extracted
CTB-GFP or control proteins (23.3 nmol/l) were incubated for 24 hours in
triplicates. For negative controls, cells with no treatment, plant-derived CTBMBP, commercial GFP, WT plant material, and commercial CTB were used.
After 24 hours of incubation, cells were washed once with PBS. Live nonfixed
cells were imaged using Nikon Eclipse, TE2000-E fluorescence microscope.
Statistical analysis. Single factor analysis of variance was used for statistical evaluation of data. Data are presented as the mean ± SD. For biochemical and retinal data, paired Student’s t-test was used to assess significance
between two groups. Differences were considered significant at P < 0.05.
Study approval. All animal studies were performed under Institutional

Animal Care and Use Committee–approved protocols. Postmortem
brain tissues of AD subjects were obtained from John Hopkins University
Alzheimer’s Disease Center, Department of Pathology, and their use was
approved by appropriate Institutional Committees.
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